TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03826875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life
Study: NCT00345787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding placebo is applied for 12weeks
Study: NCT03655522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There were two Placebos per group.
Study: NCT04248465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
Study: NCT00609323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One treatment of up to 400 cm2 Cream applied for 60 minutes.
Study: NCT00522678
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
Study: NCT00522678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive Placebo matching GW685698X via DISKUS.
Study: NCT00169962
Drug: rhDNAse (pulmozyme)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02432703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
Study: NCT01529190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02746237
Drug: KAR5585 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple ascending doses of KAR5585 (100 mg initial dose)
Study: NCT02746237
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple ascending doses of placebo (100 mg initial dose)
Study: NCT00655369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo daily dose, 3 capsules per dose during a six week treatment period.
Study: NCT03166397
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
Study: NCT03194945
Drug: CSII followed by Lina+MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
Study: NCT03194945
Drug: CSII followed by Lina
Approvals — FDA: no, EMA: no, PMDA: no
Description: short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
Study: NCT03194945
Drug: CSII followed by MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
Study: NCT03194945
Drug: CSII alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: No OHA is given after short-term intensive CSII
Study: NCT02585141
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
Study: NCT06632834
Drug: simvastatin therapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin should be administered initially with the dose of 10 mg once daily for adult and 0.25 mg/Kg once daily for children. Dose of simvastatin will be increased to the dose of 20 mg once daily for adult and 0.5 mg/Kg once daily for children after the check at 3 months without adverse effects.
Study: NCT01106014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching selexipag
Study: NCT01984138
Drug: Replens
Normalized name: Replens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replens should be applied vaginally, with a supplied applicator, three times each week.
Study: NCT04382768
Drug: Inhaled Hypertonic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care plus lipid ibuprofen 50mg tid
Study: NCT05357079
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT04442737
Drug: D/C/F/TAF FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
Study: NCT04442737
Drug: TAF/FTC FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF/FTC ARV regimen will be administered once daily.
Study: NCT04442737
Drug: INI Based Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
Study: NCT00687739
Drug: Estradiol Transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.075 mg patch per day for 5 months
Study: NCT02443831
Drug: Lymphodepletion with Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -6 to -5 prior to CD19+CD22CAR T-cell infusion.
Study: NCT02133001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
Study: NCT03629951
Drug: Oral Antipsychotics (OAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
Study: NCT03153137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablet; oral use
Study: NCT04261023
Drug: Orencia 125 MG Per 1 ML Prefilled Syringe
Normalized name: Orencia 125 MG per 1 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
Study: NCT04216524
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04216524
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04216524
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04216524
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, or PO
Study: NCT02072278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02734004
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736
Study: NCT01580995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily
Study: NCT01190930
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01190930
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01190930
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01190930
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01190930
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, PO, or IV
Study: NCT03749018
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03749018
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00766142
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00766142
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00482898
Drug: MK0359
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01845649
Drug: WC3011 Estradiol Vaginal Cream
Normalized name: Estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 14 days followed by 3 times per week for 10 weeks
Study: NCT01845649
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 14 days followed by 3 times per week for 10 weeks
Study: NCT03884062
Drug: DAAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: lab, U/S, Fibroscan \& CT if needed
Study: NCT03511378
Drug: Neulasta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Neulasta®
Study: NCT02041221
Drug: SPARC1316 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive SPARC1316.
Study: NCT02041221
Drug: SPARC1316 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02041221
Drug: SPARC1316 Dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02041221
Drug: SPARC1316 Dose 5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04571697
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.
Study: NCT04571697
Drug: Anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.
Study: NCT00632931
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
Study: NCT05082662
Drug: Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One Diclofenac tablet was administered orally.
Study: NCT05082662
Drug: Cataflam® 50 coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Diclofenac tablet was administered orally.
Study: NCT02176382
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronic acid infusion
Study: NCT03220776
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 day trial of matched placebo
Study: NCT01780545
Drug: OGX-427
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity.
Study: NCT02814097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo administered once daily for 28 consecutive days
Study: NCT03146325
Drug: BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE
Normalized name: bismuth biskalcitrate / metronidazole / tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
Study: NCT03146325
Drug: MATCHING PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
Study: NCT04672499
Drug: Placebo 150 mg tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match miricorilant 150 mg tablets for oral administration
Study: NCT02166047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match vesatolimod tablet administered orally
Study: NCT01639014
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules
Study: NCT03193216
Drug: Alginates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
Study: NCT01165502
Drug: CM3.1-AC100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAD study with repeated subcutaneous (sc) doses
Study: NCT01165502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for compound CM3.1-AC100 s.c.
Study: NCT03402321
Drug: Alvogyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: paste form with analgesic action to protect the palatal donor site and help to relief pain
Study: NCT02223871
Drug: Artemether 20 mg and lumefantrine 120mg combination tablet:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
Study: NCT01006265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally once daily
Study: NCT02538718
Drug: YTP(Ritodrine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01176435
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solution taken orally three times a day.
Study: NCT01176435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution taken orally three times a day.
Study: NCT03825016
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Diclofenac Sodium
Study: NCT00026013
Drug: hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03650361
Drug: Differin 0.3% Topical Gel
Normalized name: Differin 0.3% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
Study: NCT03116672
Drug: one dose ketorolac 10 mg
Normalized name: ketorolac Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
Study: NCT03116672
Drug: One dose Diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
Study: NCT03116672
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Placebo, 15 minutes before the clinical procedure.
Study: NCT04059172
Drug: Ibuprofen 200 mg and acetaminphen 650 mg
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Study: NCT04059172
Drug: Ibuprofen 200 mg
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Study: NCT04059172
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Study: NCT02354014
Drug: Background Regimen (BR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
Study: NCT02554903
Drug: Placebo sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
Study: NCT01885936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
Study: NCT01470664
Drug: FST-100 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: FST-100 Vehicle
Study: NCT03500263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02223013
Drug: BIBV 308 SE solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02223013
Drug: BIBV 308 SE capsule S
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03703349
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Magnesium
Study: NCT01208090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Study: NCT03807700
Drug: Experimental Denture Adhesive
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
Study: NCT02554552
Drug: YY1201 2ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: YY1201 2ml
Study: NCT02554552
Drug: Placebo 2ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: phosphate buffered saline 2ml
Study: NCT03899155
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04595565
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m² day 1-14 q21 day cycle for eight cycles
Study: NCT03899155
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03899155
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04323332
Drug: Traditional Chinese Medicine Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
Study: NCT00439647
Drug: Zoledronic acid 5 mg iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronic acid 5 mg iv given once a year.